AbCellera has announced a $200 million public offering of common shares and pre-funded warrants, significantly boosting its capital to fund internal pipeline development and corporate needs. InduPro closed a $77 million Series B financing led by The Column Group, with participation from Vida Ventures, MRL Ventures, Emerson Collective, Euclidean Capital, Solasta Ventures, Sanofi, and Eli Lilly, to advance its lead oncology program IDP-001 and broader pipeline. Silence Therapeutics completed a $175 million ADS offering at $13.50 per ADS, intending to use the proceeds to support clinical development of its siRNA candidates and general corporate purposes, extending its runway into 2029. Sources: AbCellera Reports Q2 2026 Business Results InduPro Closes $77 Million Series B Financing and Doses First Patient in Phase 1 Study of Lead Oncology Program IDP-001 Sanofi investit dans la biotech américaine InduPro spécialisée dans l'oncologie InduPro, Inc. announced that it expect...
- Get link
- X
- Other Apps